Japnese cedar pollinosis
Conditions
Interventions
Intake of shoseiryuto for 2 weeks
Intake of placebo for 2 weeks
Sponsors
Department of Otorhinolaryngology in Chiba University hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have medical history of cedar pollinosis for more than 2 years. 2)Patients who do not have nasal symtoms induced by any allergen and requier any drug treatment out of Japanese cedar pollen scattering season. 3)Positive specific IgE to cedar pollen allergen(>=class2) 4)Patients who develop more than moderate symptoms by a pollen exposure for 3 hours
Exclusion criteria
Exclusion criteria: 1) Allergy of intervention drug 2) Patients who develop mild symptoms by a pollen exposure for 3 hours. 3) Patients with nasal disease that affects the evaluation of the study 4) Severe respiratory disease, heart disease, liver disease, kidney disease, diabetes, autoimmune disease 5) Aldosteronism, myopathy, hypokalemia 6) Pregnant women and those at risk of pregnancy 7) Women who are planning pregnancy 8) Lactating woman 9) Patients treated with anti-allergic drugs within 2 week of screening 10) The patients who the doctor judged inappropriate for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total nasal symptoms induced in the environmental challernge chamber after intake of the intervention drug for 2 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between "syo" and effect of the Shoseiryuto | — |
Countries
Japan
Contacts
Public ContactSyuji Yonekura
Chiba University Graduate School Department of Otorhinolaryngology
Outcome results
None listed